Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept.
Fattizzo B, Marchetti A, Zaninoni A, Lionetti M, Riva M, Rizzo L, Pettine L, Galli N, Mazzon F, Fermo E, Maeda A, Marella A, Da Vià MC, Passamonti F, Bolli N, Barcellini W. Fattizzo B, et al. Among authors: rizzo l. Am J Hematol. 2023 Nov;98(11):E345-E348. doi: 10.1002/ajh.27072. Epub 2023 Sep 12. Am J Hematol. 2023. PMID: 37698348 No abstract available.
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. Among authors: rizzo l. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.
Bocchia M, Carella AM, Mulè A, Rizzo L, Turrini M, Abbenante MC, Cairoli R, Calafiore V, Defina M, Gardellini A, Luzi G, Patti C, Pinazzi MB, Riva M, Rossi G, Sammartano V, Rigacci L. Bocchia M, et al. Among authors: rizzo l. Pharmgenomics Pers Med. 2022 Apr 22;15:393-407. doi: 10.2147/PGPM.S346688. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 35496349 Free PMC article.
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.
Scalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, Efficace F, Latagliata R, Foà R, Breccia M. Scalzulli E, et al. Among authors: rizzo l. Ann Hematol. 2019 Aug;98(8):1919-1925. doi: 10.1007/s00277-019-03724-9. Epub 2019 Jun 5. Ann Hematol. 2019. PMID: 31168652
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E, Caocci G, Efficace F, Rizzo L, Colafigli G, Di Prima A, Pepe S, Fegatelli DA, Carmosino I, Diverio D, Latagliata R, La Nasa G, Martelli M, Foà R, Breccia M. Scalzulli E, et al. Among authors: rizzo l. Ann Hematol. 2021 May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7. Ann Hematol. 2021. PMID: 33677654
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?
Campagna A, De Benedittis D, Fianchi L, Scalzulli E, Rizzo L, Niscola P, Piccioni AL, Di Veroli A, Mancini S, Villivà N, Martini T, Mohamed S, Carmosino I, Criscuolo M, Fenu S, Aloe Spiriti MA, Buccisano F, Mancini M, Tafuri A, Breccia M, Poloni A, Latagliata R. Campagna A, et al. Among authors: rizzo l. J Clin Med. 2022 May 5;11(9):2596. doi: 10.3390/jcm11092596. J Clin Med. 2022. PMID: 35566719 Free PMC article.
619 results